hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06384287, orgStudyIdInfo id: APHP231342, briefTitle: Peripheral Tissue Perfusion in Intensive Care, acronym: INPPEREA, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2027-05, completionDateStruct date: 2027-05, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Assistance Publique - Hôpitaux de Paris, class: OTHER, descriptionModule briefSummary: Tissue perfusion has been identified as an early prognosis factor in patients admitted to intensive care. However, little is known about the effects of different hemodynamic interventions performed in clinical routine on peripheral tissue perfusion.The aim of this work is to study the kinetics of CRT and local skin blood flow following therapeutic intervention (fluid challenge, vasopressor or inotropic drug)., conditionsModule conditions: Acute Circulatory Failure, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 180, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Skin blood flow variations, secondaryOutcomes measure: Capillary refill time, secondaryOutcomes measure: Mottling score, secondaryOutcomes measure: correlation between Skin blood flow and CRT (baseline and variations), secondaryOutcomes measure: correlation between skin blood flow and Cardiac output, secondaryOutcomes measure: correlation between skin blood flow and mean arterial pressure, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06384274, orgStudyIdInfo id: NEUniversity, briefTitle: The Effect of Emotional Freedom Technique and Virtual Reality Glasses on Anxiety and Vital Signs, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-10-01, primaryCompletionDateStruct date: 2024-10-01, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Necmettin Erbakan University, class: OTHER, descriptionModule briefSummary: The aim of the study was to examine the effects of the emotional freedom technique and virtual reality glasses applied to individuals receiving hyperbaric oxygen therapy for the first time on anxiety and vital signs. The hypotheses of this research are that there is a difference between the emotional liberation technique and virtual reality glasses groups and the control group in terms of anxiety and vital signs., conditionsModule conditions: Anxiety, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 75, type: ESTIMATED, armsInterventionsModule interventions name: Emotional Freedom Technique, interventions name: Virtual Reality Glasses, outcomesModule primaryOutcomes measure: State Anxiety Inventory (STAI), secondaryOutcomes measure: Blood Pressure, secondaryOutcomes measure: Pulse, secondaryOutcomes measure: Respiration, secondaryOutcomes measure: Body Temperature, secondaryOutcomes measure: Oxygen Saturation, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Gülsüm Gürsoy Açikgöz, city: Konya, state: Meram, country: Turkey, contacts name: gülsüm GÜRSOY AÇIKGÖZ, role: CONTACT, phone: 05535553934, email: 2gulsum5@gmail.com, geoPoint lat: 37.87135, lon: 32.48464, hasResults: False
protocolSection identificationModule nctId: NCT06384261, orgStudyIdInfo id: OV-AML-1231, briefTitle: A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2027-01, completionDateStruct date: 2027-06, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: OncoVerity, Inc., class: INDUSTRY, descriptionModule briefSummary: The goal of this clinical trial is to learn if participants treated with the experimental drug cusatuzumab added to venetoclax and azacitidine works to treat acute myeloid leukemia (AML) compared to venetoclax and azacitidine. Venetoclax and azacitidine are drugs commonly used to treat AML in patients that are unable to receive chemotherapy to treat AML. The main question the clinical trial aims to answer is does cusatuzumab added to venetoclax and azacitidine prolong the length of time participants live compared to venetoclax and azacitidine?, conditionsModule conditions: Leukemia, Myeloid, Acute, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Cusatuzumab, interventions name: Venetoclax, interventions name: Azacitidine, outcomesModule primaryOutcomes measure: Overall survival, secondaryOutcomes measure: Complete Remission rate (CR), secondaryOutcomes measure: Event-free survival (EFS), secondaryOutcomes measure: Composite CR rate (CRc), secondaryOutcomes measure: Rate of CRh and CRi, secondaryOutcomes measure: Duration of CR, secondaryOutcomes measure: Time to first CR, secondaryOutcomes measure: Rate of minimal residual disease (MRD) negativity in patients achieving CR, CRh, or CRi, secondaryOutcomes measure: Proportion of participants proceeding to hematopoietic stem cell transplantation (HSCT), secondaryOutcomes measure: OS in participants undergoing HSCT, secondaryOutcomes measure: Incidence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to study drug discontinuation, secondaryOutcomes measure: Incidence of dose modifications due to AEs, secondaryOutcomes measure: Number of participants with abnormal laboratory test results, secondaryOutcomes measure: Incidence of anti-drug antibodies (ADA) and neutralizing antibodies (NAb), secondaryOutcomes measure: Overall survival in subgroups of participants according to specified AML risk stratification models, secondaryOutcomes measure: Complete Remission rate, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06384248, orgStudyIdInfo id: LTC004-205, briefTitle: Phase II Clinical Study of LTC004 in Patients With Advanced Sarcoma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-26, primaryCompletionDateStruct date: 2025-12-28, completionDateStruct date: 2025-12-28, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Letolab, class: INDUSTRY, descriptionModule briefSummary: This is a phase II clinical study to evaluate the safety, tolerability and preliminary antitumor activity of LTC004 in patients with locally advanced or metastatic sarcoma；Enrollment of 10 evaluable subjects in Phase I. If ≥2 subjects experience objective remission or SD lasting \>12 weeks, proceed to Phase II to enroll an additional 20 evaluable subjects to further evaluation of the safety and efficacy of LTC004, conditionsModule conditions: Unresectable or Metastatic Sarcoma, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: LTC004, outcomesModule primaryOutcomes measure: ORR, secondaryOutcomes measure: DOR, secondaryOutcomes measure: PFS rate, secondaryOutcomes measure: OS, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06384235, orgStudyIdInfo id: LTC004-203, briefTitle: Phase II Clinical Study of LTC004 in Patients With mCRC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-25, primaryCompletionDateStruct date: 2025-08-23, completionDateStruct date: 2025-08-23, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Letolab, class: INDUSTRY, descriptionModule briefSummary: This is a phase II clinical study to evaluate the safety and antitumor activity of LTC004 in patients with locally advanced or metastatic CRC，Enrollment of 10 evaluable subjects in Phase I. If ≥2 subjects experience objective remission，proceed to Phase II to enroll an additional 20 evaluable subjects to further evaluation of the safety and efficacy of LTC004, conditionsModule conditions: Locally Advanced or Metastatic CRC, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: LTC004, outcomesModule primaryOutcomes measure: ORR, secondaryOutcomes measure: DOR, secondaryOutcomes measure: PFS, secondaryOutcomes measure: OS, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06384222, orgStudyIdInfo id: 235513, secondaryIdInfos id: NCI-2024-03418, type: REGISTRY, domain: NCI Clinical Trials Reporting Program (CTRP), briefTitle: Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) MRI as a Response Monitoring Tool to Neoadjuvant Abiraterone, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-30, primaryCompletionDateStruct date: 2027-07-31, completionDateStruct date: 2027-07-31, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Ivan de Kouchkovsky, MD, class: OTHER, descriptionModule briefSummary: This study will evaluate the use of hyperpolarized 13C MRI (HP 13C MRI) and the HP-derived 13C pyruvate-to-lactate conversion rate constant (kPL) as an early response biomarker in men with treatment-naïve, high-risk, localized or locally advanced prostate cancer receiving neoadjuvant therapy., conditionsModule conditions: High Risk Prostate Carcinoma, conditions: Prostate Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 32, type: ESTIMATED, armsInterventionsModule interventions name: Abiraterone acetate, interventions name: Prednisone, interventions name: Hyperpolarized [1-13C] pyruvate (HP 13C), interventions name: Magnetic Resonance Imaging (MRI), interventions name: Non-investigational radical prostatectomy (RP), interventions name: Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT), outcomesModule primaryOutcomes measure: Mean changes in intratumoral KPL, secondaryOutcomes measure: Pathological response rate, secondaryOutcomes measure: Proportion of participants with treatment-related adverse events, secondaryOutcomes measure: Proportion of participants completing RP, secondaryOutcomes measure: Median Time to Biochemical Recurrence, secondaryOutcomes measure: Proportion of participants with a >=50% decline in PSA level from baseline (PSA50) response, secondaryOutcomes measure: Proportion of participants with a >=90% decline in PSA level from baseline (PSA90) response, secondaryOutcomes measure: Mean PSA nadir, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of California, San Francisco, city: San Francisco, state: California, zip: 94143, country: United States, contacts name: Maya Aslam, role: CONTACT, phone: 415-514-8987, email: Maya.Aslam@ucsf.edu, contacts name: Ivan de Kouchkovsky, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 37.77493, lon: -122.41942, hasResults: False
protocolSection identificationModule nctId: NCT06384209, orgStudyIdInfo id: FBplus2024, briefTitle: The Friendship Bench Plus Trial, acronym: FB+, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2026-12-28, completionDateStruct date: 2027-02-28, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: University of Bern, class: OTHER, collaborators name: University of Zimbabwe, collaborators name: Swiss National Science Foundation, descriptionModule briefSummary: The goal of this randomised controlled trial is to enhance the Friendship Bench intervention with antidepressants in adults with moderate to severe depression. The main questions it aims to answer are:1. Is the combination of the Friendship Bench with nurse-led antidepressants prescribing superior to the Friendship Bench alone?2. What are the barriers and enablers for the prescription of antidepressants by non-specialists in primary care?Type of study: Randomized controlled superiority trialParticipants will be randomly selected and allocated into the control arm or intervention arm. Participants in the control arm will receive six sessions of the Friendship Bench Problem Solving Therapy while those in the intervention arm will receive the Friendship Bench intervention plus Fluoxetine (Sertraline for breastfeeding women)., conditionsModule conditions: Major Depressive Disorder, conditions: Severe Depressive Episode Without Psychotic Symptoms, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 296, type: ESTIMATED, armsInterventionsModule interventions name: Friendship Bench intervention, interventions name: Antidepressants -Fluoxetine, outcomesModule primaryOutcomes measure: Treatment response, secondaryOutcomes measure: Remission, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Zimbabwe, city: Harare, country: Zimbabwe, contacts name: Rukudzo Mwamuka, Mbchb,MMed(Psychiatry), role: CONTACT, phone: +263777065549, email: ruemwamuka.tsungu@gmail.com, contacts name: Jermaine Dambi, PhD, role: CONTACT, phone: +263773444911, email: jermaine.dambi@friendshipbench.io, geoPoint lat: -17.82772, lon: 31.05337, hasResults: False
protocolSection identificationModule nctId: NCT06384183, orgStudyIdInfo id: KS-1000, briefTitle: Kerecis Real World Registry, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07, primaryCompletionDateStruct date: 2026-06, completionDateStruct date: 2027-06, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Kerecis Ltd., class: INDUSTRY, descriptionModule briefSummary: Multi-center, observational (i.e., non-interventional), open-label, real-world Registry on the Use of Kerecis Devices, conditionsModule conditions: Wounds, conditions: Pressure Ulcer, conditions: Diabetic Foot Ulcer, conditions: Venous Leg Ulcer, conditions: Surgical Wound, conditions: Soft Tissue Reinforcement, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: OTHER, enrollmentInfo count: 600, type: ESTIMATED, armsInterventionsModule interventions name: Kerecis Fish Skin Graft, outcomesModule primaryOutcomes measure: Fish Skin Graft Device Related failure, primaryOutcomes measure: Fish Skin Graft Device related allergy, primaryOutcomes measure: Target Wound Infection, secondaryOutcomes measure: Complete Wound Healing, secondaryOutcomes measure: Complete Wound Closure, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06384157, orgStudyIdInfo id: INDV-2000-201, briefTitle: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-08, completionDateStruct date: 2025-09, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Indivior Inc., class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to measure safety and efficacy and to determine dose-response relationship for INDV-2000 in participants with moderate to severe Opioid Use Disorder (OUD) who are new to treatment, have recently initiated or completed short-term medically supervised withdrawal with transmucosal (TM) buprenorphine, and are interested in transitioning to a non opioid treatment., conditionsModule conditions: Opioid Use Disorder, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, maskingDescription: This is a randomized, double-blind, placebo-controlled study where the investigator, assessor, sponsor and participant are masked., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: INDV-2000, interventions name: Placebo, outcomesModule primaryOutcomes measure: Proportion (probability) of participants without treatment failure by the end of Week 12 (Day 85)., secondaryOutcomes measure: Proportion (probability) of visits with opioid abstinence while participants are on IMP alone., secondaryOutcomes measure: Participant's percentage of visits with opioid abstinence during the whole study follow-up., secondaryOutcomes measure: Incidence, severity and relatedness of adverse events, treatment-emergent adverse events, serious adverse events and events leading to discontinuation and deaths., secondaryOutcomes measure: Opioid Craving Assessment, secondaryOutcomes measure: Cmax on Day 1 and Day 15/16, secondaryOutcomes measure: Tmax on Day 1 and Day 15/16, secondaryOutcomes measure: AUC0-24 on Day 1 and Day 15/16, secondaryOutcomes measure: Cavg on Day 1 and Day 15/16, secondaryOutcomes measure: Cmin on Day 1 and Day 15/16, secondaryOutcomes measure: CL/F on Day 1 and Day 15/16, secondaryOutcomes measure: Clinical Opiate Withdrawal Scale (COWS) score, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06384144, orgStudyIdInfo id: 23QC8155, briefTitle: Machine Learning Miscarriage Management Clinical Decision Support Tool Study, acronym: MLMM, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2026-06-01, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Imperial College London, class: OTHER, descriptionModule briefSummary: Machine learning used to develop an algorithm to determine chance of success with expectant or medical management for an individual patient. Taking into account the following objective measures:* Demographics: Maternal Age, Parity* History: Previous CS, Previous SMM/MVA, Previous Myomectomy* Gestation by LMP* Presenting symptoms: Bleeding score, Pain score* USS Measurements: CRL, GS, RPOC 3 dimensions, Vascularity* Discrepancy between gestation by CRL and LMPAudit to collate 1000 cases and identify features contributing to an algorithm that can predict outcome of miscarriage management for individualized case management., conditionsModule conditions: Miscarriage in First Trimester, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule interventions name: Expectant Management of First Trimester Miscarriage, interventions name: Medical Management of First Trimester Miscarriage, outcomesModule primaryOutcomes measure: Machine learning predictive model development for miscarriage management outcomes., secondaryOutcomes measure: Prospective audit to test and validate predictive model, eligibilityModule sex: FEMALE, minimumAge: 16 Years, maximumAge: 55 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Imperial College Heatlhcare NHS Trust, status: RECRUITING, city: London, zip: W12 0HS, country: United Kingdom, contacts name: Sughashini Murugesu, role: CONTACT, phone: 07988390772, email: sughashini.murugesu@nhs.net, geoPoint lat: 51.50853, lon: -0.12574, hasResults: False
protocolSection identificationModule nctId: NCT06384131, orgStudyIdInfo id: ABI-4334-102, secondaryIdInfos id: 2024-511051-18, type: EUDRACT_NUMBER, briefTitle: A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B Virus Infection, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2025-04-22, completionDateStruct date: 2025-04-22, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Assembly Biosciences, class: INDUSTRY, descriptionModule briefSummary: This is a randomized, blinded, placebo-controlled, dose-ranging Phase 1b study of the safety, PK, and antiviral activity of ABI-4334 in treatment-naïve or off-treatment chronic Hepatitis B virus (cHBV) subjects that are Hepatitis B e antigen (HBeAg) positive or negative. The study will enroll up to 5 sequential cohorts of 10 subjects each, for a total of up to 50 subjects, randomized 8:2 to receive ABI-4334 or placebo., conditionsModule conditions: Chronic Hepatitis B, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, maskingDescription: Triple (Participant, Care Provider, Investigator), whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: ABI-4334, interventions name: Placebo, outcomesModule primaryOutcomes measure: Primary Outcome Measure, secondaryOutcomes measure: Maximum Plasma Concentration (Cmax) of ABI-4334 in subjects with cHBV, secondaryOutcomes measure: Minimum Plasma Concentration (Cmin) of ABI-4334 in subjects with cHBV, secondaryOutcomes measure: Area Under Plasma Concentration-Time Curve (AUC) of ABI-4334 in subjects with cHBV, secondaryOutcomes measure: Time to Maximum Plasma Concentration (Tmax) of ABI-4334 in subjects with cHBV, secondaryOutcomes measure: Elimination half-life (t1/2) of ABI-4334 in subjects with cHBV, secondaryOutcomes measure: To evaluate the changes in HBV DNA (IU/mL or Log IU/mL) in subjects with cHBV, secondaryOutcomes measure: Proportion of subjects with HBV DNA < lower limit of quantification (LLOQ) and/or limit of detection (LOD), secondaryOutcomes measure: Mean time elapsed to subjects achieving HBV DNA < LLOQ and/or LOD, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False